Prognosis of Japanese metastatic renal cell carcinoma patients in the targeted therapy era
Sei Naito(Yamagata University), Norihiko Tsuchiya(Yamagata University), Shingo Hatakeyama(Hirosaki University), Tomonori Habuchi(Akita University), Hayato Yamamoto(Hirosaki University), Akihiro Ito(Tohoku University), Sadafumi Kawamura(Miyagi Prefectural Hospital Organization), Kazuyuki Numakura(Akita University), Tomoyuki Kato(Aichi Cancer Center), Renpei Kato(Iwate Medical University), Wataru Obara(Iwate Medical University), Shintaro Narita(Akita University), Soichiro Ogawa(Fukushima Medical University), Hiroyuki Nishiyama(University of Tsukuba), Chikara Οhyama(Hirosaki University), Yoshihide Kawasaki(Tohoku University), Yoshiyuki Kojima(Fukushima Medical University), Shuya Kandori(University of Tsukuba), Hisanobu Adachi(Sendai Shakai Hoken Hospital), Tomoyuki Koguchi(Fukushima Medical University)
Cited by 10
Related Papers
A cross-population atlas of genetic associations for 220 human phenotypes
|Nature Genetics|2021|2.4k
Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial
|The Lancet Oncology|2017|1.8k
Avelumab Maintenance Therapy for Advanced or Metastatic Urothelial Carcinoma
|New England Journal of Medicine|2020|1.5k
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603